Novartis' Rhapsido shows sustained efficacy through 52 weeks in Phase III chronic inducible urticaria trial
NVS•Novartis reported that Rhapsido sustained symptom relief through 52 weeks across three chronic inducible urticaria subtypes in the Phase III RemIND trial. Safety remained consistent with previous studies, and the findings will support additional regulatory submissions.
1. Trial results
Novartis reported that Rhapsido (remibrutinib) sustained symptom relief through 52 weeks across three chronic inducible urticaria subtypes in the Phase III RemIND trial. Patients who switched from placebo achieved similar long-term responses, and safety remained consistent with previous studies. The results will support additional regulatory submissions for chronic inducible urticaria and will be presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting 2026.
